Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer

This study is testing a medication called gilteritinib to see if it can help patients with advanced lung cancer that has stopped responding to other treatments. Because this drug has shown promise in lab tests against resistant cancer cells, researchers want to see if it can provide a new option for people whose current therapy is no longer working.

You may be able to join if you have stage 4 non-small cell lung cancer with an ALK genetic change and have already tried other targeted therapies and chemotherapy. You must also have stable health and meet specific criteria regarding previous treatments and any past spread of cancer to the brain.

You will receive the study medication, gilteritinib, while doctors monitor you closely to check for side effects and how your body reacts to the drug. The study involves regular health check-ins, which include blood tests, imaging scans like MRIs or CTs, heart ultrasounds, and filling out surveys about how you are feeling.

The study is currently recruiting participants in Los Angeles, California; Washington, D.C.; and Ann Arbor, Michigan. Please speak with your oncologist to see if a center near you is accepting new patients.